Literature DB >> 7815512

The transcripts from the sequences flanking the short component of Marek's disease virus during latent infection form a unique family of 3'-coterminal RNAs.

E A McKie1, E Ubukata, S Hasegawa, S Zhang, M Nonoyama, A Tanaka.   

Abstract

We have constructed a cDNA library using poly(A)+ RNA from the stably transformed Marek's disease virus cell line MKT-1 and isolated cDNAs specific to the short internal repeat region of the BamHI-A fragment of the viral genome. Four distinct classes of cDNA were identified through sequence analysis of the 5' and 3' termini of each clone isolated, and a representative of each class was chosen for complete sequencing. These cDNAs were mapped on the basis of the genomic nucleotide sequence of this region, and a family of 3'-coterminal overlapping transcripts consisting of several highly spliced species, was identified. PCR was used to amplify specific regions of each cDNA, which were subcloned and used to generate riboprobes. These riboprobes hybridized to a variety of transcripts in poly(A)+ RNA fractions isolated from cells either lytically or latently infected with Marek's disease virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815512      PMCID: PMC188711     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Biochemical evidence of the nonintegrated status of Marek's disease virus DNA in virus-transformed lymphoblastoid cells of chicken.

Authors:  A Tanaka; S Silver; M Nonoyama
Journal:  Virology       Date:  1978-07-01       Impact factor: 3.616

2.  Homologous recognition of a promoter domain common to the MSV LTR and the HSV tk gene.

Authors:  B J Graves; P F Johnson; S L McKnight
Journal:  Cell       Date:  1986-02-28       Impact factor: 41.582

3.  Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials.

Authors:  B H Rispens; H van Vloten; N Mastenbroek; H J Maas; K A Schat
Journal:  Avian Dis       Date:  1972-04       Impact factor: 1.577

4.  Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II.

Authors:  W S Dynan; R Tjian
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

5.  Spontaneous and induced herpesvirus genome expression in Marek's disease tumor cell lines.

Authors:  B W Calnek; W R Shek; K A Schat
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

6.  Structure of Marek's disease virus DNA: detailed restriction enzyme map.

Authors:  K Fukuchi; M Sudo; Y S Lee; A Tanaka; M Nonoyama
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

Review 7.  Organization and expression of eucaryotic split genes coding for proteins.

Authors:  R Breathnach; P Chambon
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

8.  A catalogue of splice junction sequences.

Authors:  S M Mount
Journal:  Nucleic Acids Res       Date:  1982-01-22       Impact factor: 16.971

9.  The structure of Marek disease virus DNA: the presence of unique expansion in nonpathogenic viral DNA.

Authors:  K Fukuchi; A Tanaka; L W Schierman; R L Witter; M Nonoyama
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

10.  Size and composition of Marek's disease virus deoxyribonucleic acid.

Authors:  L F Lee; E D Kieff; S L Bachenheimer; B Roizman; P G Spear; B R Burmester; K Nazerian
Journal:  J Virol       Date:  1971-03       Impact factor: 5.103

View more
  10 in total

1.  The complete unique long sequence and the overall genomic organization of the GA strain of Marek's disease virus.

Authors:  L F Lee; P Wu; D Sui; D Ren; J Kamil; H J Kung; R L Witter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Transactivation of latent Marek's disease herpesvirus genes in QT35, a quail fibroblast cell line, by herpesvirus of turkeys.

Authors:  T Yamaguchi; S L Kaplan; P Wakenell; K A Schat
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  The genome of a very virulent Marek's disease virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; D L Rock; G F Kutish
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Recombinant Marek's disease virus (MDV)-derived lymphoblastoid cell lines: regulation of a marker gene within the context of the MDV genome.

Authors:  M S Parcells; R L Dienglewicz; A S Anderson; R W Morgan
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

5.  Insertion of tandem direct repeats consisting of avian leukosis virus LTR sequences into the inverted repeat region of Marek's disease virus type 1 DNA.

Authors:  M Sakaguchi; K Sonoda; K Matsuo; G S Zhu; K Hirai
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

6.  Detection of latency-associated transcripts of equid herpesvirus 1 in equine leukocytes but not in trigeminal ganglia.

Authors:  P M Chesters; R Allsop; A Purewal; N Edington
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

7.  Marek's disease virus latency-associated transcripts belong to a family of spliced RNAs that are antisense to the ICP4 homolog gene.

Authors:  J L Cantello; M S Parcells; A S Anderson; R W Morgan
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  Alterations of the MDV oncogenic regions in an MDV transformed lymphoblastoid cell line.

Authors:  E Le Rouzic; P Thoraval; M Afanassieff; Y Cherel; G Dambrine; B Perbal
Journal:  Mol Pathol       Date:  2002-08

9.  Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC-MSB1 MDV-transformed lymphoblastoid cells.

Authors:  Q Xie; A S Anderson; R W Morgan
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Transcriptional profiling of Marek's disease virus genes during cytolytic and latent infection.

Authors:  Mohammad Heidari; Marianne Huebner; Dmitry Kireev; Robert F Silva
Journal:  Virus Genes       Date:  2008-02-12       Impact factor: 2.332

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.